Germany · Delayed Price · Currency is EUR Protara Therapeutics Statistics
Total Valuation
FRA:1KPA has a market cap or net worth of EUR 223.72 million. The enterprise value is 111.92 million.
| Market Cap | 223.72M |
| Enterprise Value | 111.92M |
Important Dates
The next estimated earnings date is Monday, March 9, 2026.
| Earnings Date | Mar 9, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 38.59M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +129.86% |
| Shares Change (QoQ) | +0.00% |
| Owned by Insiders (%) | 2.51% |
| Owned by Institutions (%) | 64.10% |
| Float | 35.48M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 1.98 |
| P/TBV Ratio | 1.98 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.48 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -2.69 |
Financial Position
The company has a current ratio of 13.69, with a Debt / Equity ratio of 0.03.
| Current Ratio | 13.69 |
| Quick Ratio | 13.49 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.07 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -49.42% and return on invested capital (ROIC) is -33.59%.
| Return on Equity (ROE) | -49.42% |
| Return on Assets (ROA) | -31.30% |
| Return on Invested Capital (ROIC) | -33.59% |
| Return on Capital Employed (ROCE) | -44.37% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -1.45M |
| Employee Count | 33 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +123.59% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +123.59% |
| 50-Day Moving Average | 4.53 |
| 200-Day Moving Average | 3.35 |
| Relative Strength Index (RSI) | 69.57 |
| Average Volume (20 Days) | 23 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 4.81 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -50.95M |
| Pretax Income | -45.09M |
| Net Income | -45.09M |
| EBITDA | -50.65M |
| EBIT | -50.95M |
| Earnings Per Share (EPS) | -1.18 |
Balance Sheet
The company has 113.07 million in cash and 3.12 million in debt, giving a net cash position of 110.77 million.
| Cash & Cash Equivalents | 113.07M |
| Total Debt | 3.12M |
| Net Cash | 110.77M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 112.75M |
| Book Value Per Share | 2.92 |
| Working Capital | 107.16M |
Cash Flow
In the last 12 months, operating cash flow was -41.53 million and capital expenditures -59,661, giving a free cash flow of -41.59 million.
| Operating Cash Flow | -41.53M |
| Capital Expenditures | -59,661 |
| Free Cash Flow | -41.59M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
FRA:1KPA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -129.86% |
| Shareholder Yield | -129.86% |
| Earnings Yield | -20.15% |
| FCF Yield | -18.59% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |